Transient Antibody Deficiency and Abnormal T Suppressor Cells Induced by Phenytoin

New England Journal of Medicine

Volumn 306, Issue 7, 1982, Pages 406-409

  Dosch, Hans Michael ^a   Jason, Jeannine ^a   Gelfand, Erwin W ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYZINE; IMMUNOGLOBULIN G; PHENYTOIN;

ADVERSE DRUG REACTION; ANTIBODY PRODUCTION; C CELL; CASE REPORT; HYPOGAMMAGLOBULINEMIA; IMMUNE DEFICIENCY; IMMUNOPATHOLOGY; INJURY; ORAL DRUG ADMINISTRATION; SCHOOL CHILD; SEIZURE; SUPPRESSOR CELL; THERAPY; TRAUMATIC EPILEPSY;

EID: 0020048699     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198202183060707     Document Type: Article

References (30)

1. Waldmann T.A., Durm M., Broder S., Blackman M., Blaese K.M., Strober W. Role of suppressor T cells in palhogenesis of common variable hypogammaglobulinaemia. Lancet. 1974; 2:609-613
2. Herrod H.G., Buckley R.H. Use of a human plaque-forming cell assay to study peripheral blood bursa-equivalent cell activation and excessive suppressor cell activity in humoral immunodeficiency. J Clin Invest. 1979; 63:868-876
3. Dosch H.-M., Percy M.E., Gelfand E.W. Functional differentiation of B lymphocytes in congenital agammaglobulinemia. I. Generation of hemolytic plaque-forming cells. J Immunol. 1977; 119:1959-1964
4. Dosch H.-M., Gelfand E.W. Functional differentiation of B lymphocytes in agammaglobulinemia. III. Characterization of spontaneous suppressor cell activity. J Immunol. 1978; 121:2097-2105
5. Dosch. Generation of human plaque-forming cells in culture: tissue distribution, antigenic and cellular requirements. J Immunol. 1977; 118:302-308
6. Dosch H.-M., Shore A., Gelfand E.W. Regulation of the specific plaque-forming cell response in man: restraint of B cell responsiveness. Eur J Immunol. 1979; 9:702-707
7. Gelfand E.W., Dosch H.-M., Hastings D., Shore A. Lithium: a modulator of cyclic AMP-dependent events in lymphocytes? Science. 1979; 203:365-367
8. Dosch H.-M., Matheson D.S., Schuurman R.K.B., et al. Anti-suppressor cell effect of lithium in vitro and in vivo. In: Rossof AH, Robinson WH, eds. Lithium effects on granulopoiesis and immune function. New York: Plenum Press, 1980: 47-62.
9. Sorrell T.C., Forbes I.J., Burness F.R., Rischbieth R.H.C. Depression of immunological function in patients treated with phenytoin sodium (sodium diphenylhydantoin). Lancet. 1971; 2:1233-1235
10. Grob P.J., Herold G.E. Immunological abnormalities and hydantoins. Br Med J. 1972; 2:561-563
11. Sorrell T.C., Forbes I.J. Depression of immune competence by phenytoin and carbamazepine: studies in vivo and in vitro. Clin Exp Immunol. 1975; 20:273-285
12. Hassell T.M., Page R.C., Narayanan A.S., Cooper C.G. Diphenylhydantoin (Dilantin) gingival hyperplasia: drug-induced abnormality of connective tissue. Proc Natl Acad Sci USA. 1976; 73:2909-2912
13. Ooi B.S., Kant K.S., Hanenson I.B., Pesce A.J., Pollak V.E. Lymphocytotoxins in epileptic patients receiving phenytoin. Clin Exp Immunol. 1977; 30:56-61.
14. Li F.P., Willard D.R., Goodman R., Vawter G. Malignant lymphoma after diphenylhydantoin (Dilantin) therapy. Cancer. 1975; 36:1359-1362
15. Finkelman I., Arieff A.J. Untoward effects of phenytoin sodium in epilepsy. JAMA. 1942; 118:1209-1212
16. Van Wyk J.J., Hoffmann C.R. Periarteritis nodosa: a case of fatal exfoliative dermatitis resulting from “dilantin sodium” sensitization. Arch Intern Med. 1948; 81:605-611
17. Michael J.R., Mitch W.E. Reversible renal failure and myositis caused by phenytoin hypersensitivity. JAMA. 1976; 236:2773-2775
18. Sheth K.J., Casper J.T., Good R.A. Interstitial nephritis due to phenytoin hypersensitivity. J Pediatr. 1977; 91:438-441
19. Schwarz U., Lämmle B., Six P., Scollo B., Haas H.G. Autoimmun polyendokrinopathie bei IgA-Mangel. Schweiz Med Wochenschr. 1978; 108:1912-1913
20. Slavin B.N., Fenton G.M., Laundy M., Reynolds E.H. Serum immunoglobulins in epilepsy. J Neurol Sci. 1974; 23:353-357
21. Aarli J.A. Drug-induced IgA deficiency in epileptic patients. Arch Neurol. 1976; 33:296-299
22. Seager J., Jamison D.L., Wilson J., Hayward A.R., Soothill J.F. IgA deficiency, epilepsy, and phenytoin treatment. Lancet. 1975; 2:632-635
23. Alareón-Segovia D., Fishbein E., Reyes P.A., Dies H., Shwadsky S. Antinuclear antibodies in patients on anticonvulsant therapy. Clin Exp Immunol. 1972; 12:39-47.
24. MacKinney A.A., Booker H.E. Diphenylhydantoin effects on human lymphocytes in vitro and in vivo: an hypothesis to explain some drug reactions. Arch Intern Med. 1972; 129:988-992
25. Ferrendelli J.A. Phenytoin: cyclic nucleotide regulation in the brain. Adv Neurol. 1980; 27:429-433
26. Alareón-Segovia D. Drug-induced lupus syndromes. Mayo Clin Proc. 1969; 44:664-681
27. Krüger G. Effect of Dilantin in mice. I. Changes in the lymphoreticular tissue after acute exposure. Virchows Arch [Pathol Anat]. 1970; 349:297-311.
28. Kanoh T., Uchino H. Immunodeficiency and epilepsy. Lancet. 1976; 1:860-861
29. Gelfand E.W., Dosch H.M. In vitro functional heterogeneity of cellular and humoral immune deficiency states. In: Fauci AS, Ballieux RE, eds. In vitro induction and measurements of antibody synthesis in man. New York: Academic Press, 1979: 309-24.
30. Blaese R.M., Weiden P.L., Koski J., Dooley N. Infectious agammaglobulinemia: transmission of immunodeficiency with grafts of agammaglobulinemic cells. J Exp Med. 1974; 140:1097-1101